Regulatory and Public Policy Engagement

Turning Point Brands, Inc., views regulatory and policy matters as not only a critical piece of its decision making process but also as an advantage in the marketplace. With an office in Washington, D.C., the Turning Point team actively engages with stakeholders at all levels of government and industry to further policies that promote product innovation and adult consumer choice. This provides the added benefit to our team of access to current information related to constantly evolving laws and regulations impacting our business.

Policies We Support

We focus our efforts in the following policy areas:

  • Promoting responsible marketing practices
  • Preventing youth access and exposure
  • Supporting adult consumer choice
  • Driving policies that support innovation in alternatives to cigarettes

Industry Engagement

Turning Point participates in a number of national and local trade associations whose values align with our policies, including those listed below.

Regulatory Engagement

Our portfolio of products is subject to a number of laws and regulations. Where appropriate, Turning Point engages directly in the legislative or policymaking process. To that end, our legal team monitors and frequently provides comments to proposed regulations impacting our products. Representatives from Turning Point frequently interact with regulatory agencies, including the U.S. Food and Drug Administration (FDA), Customs and Border Protection (CBP), and the Alcohol and Tobacco Tax and Trade Bureau (TTB), to provide feedback on proposed actions and policy proposals.

The U.S. Food and Drug Administration is a key regulator of our product lineup. Since 2010, Turning Point has submitted numerous regulatory submissions on its products, including 250 products prior to September 9, 2020, when newly deemed products were required to submit premarket tobacco applications, or PMTAs.

Turning Point Brands supports reasonable regulation of its product categories and believes the FDA process will allow responsibly marketed and manufactured products to continue to be sold in the marketplace. We have invested significant time and resources into the PMTA process, and we expect to continue our engagement with FDA during the review of our submissions.

You can read more about the FDA premarket process here.